中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.015 seconds)

    ORGANIC COMPOUNDS
    1.
    发明申请
    ORGANIC COMPOUNDS 有权

    公开(公告)号：US20250101029A1

    公开(公告)日：2025-03-27

    申请号：US18847121

    申请日：2023-03-14

    Applicant: INTRA-CELLULAR THERAPIES, INC.

    Inventor： Peng LI ,  Robert E. DAVIS ,  Gretchen SNYDER ,  Allen A. FIENBERG

    IPC: C07D487/14 ,  A61K31/4985

    Abstract: The invention relates to a particular enantiomer of a substituted heterocycle fused gamma-carboline, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, and pathways involving the dopamine D1 and D2 receptor signaling system.

    ORGANIC COMPOUND
    2.
    发明申请
    ORGANIC COMPOUND 有权

    公开(公告)号：US20250092045A1

    公开(公告)日：2025-03-20

    申请号：US18968542

    申请日：2024-12-04

    Applicant: INTRA-CELLULAR THERAPIES, INC.

    Inventor： Peng LI ,  Qiang ZHANG ,  Robert E. DAVIS

    IPC: C07D471/16 ,  A61K9/16

    Abstract: The invention relates to a particular substituted heterocycle fused gamma-carboline, in free, or pharmaceutically acceptable salt, and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), and/or pathways involving the dopamine D1 and D2 receptor signaling system.

    NOVEL USES
    3.
    发明申请
    NOVEL USES 有权

    公开(公告)号：US20210379072A1

    公开(公告)日：2021-12-09

    申请号：US17287478

    申请日：2019-10-21

    Applicant: INTRA-CELLULAR THERAPIES, INC.

    Inventor： Robert E. DAVIS ,  Kimberly E. VANOVER

    IPC: A61K31/519 ,  A61P25/16

    Abstract: The disclosure provides methods, treatments and materials for treating diseases or disorders associated with the dopamine D1 receptor intracellular pathway. In particular, the present disclosure provides for methods of treating such diseases and disorders in combination with a dopamine replacement therapy.

    ORGANIC COMPOUND
    4.
    发明公开
    ORGANIC COMPOUND 审中-公开

    公开(公告)号：US20240327436A1

    公开(公告)日：2024-10-03

    申请号：US18741739

    申请日：2024-06-12

    Applicant: INTRA-CELLULAR THERAPIES, INC.

    Inventor： Peng LI ,  Robert E. DAVIS ,  Kimberly Vanover

    IPC: C07D519/00

    CPC classification number: C07D519/00

    Abstract: The invention relates to pharmaceutical compositions comprising the compound of Formula I,




    and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity.

    NOVEL METHODS
    5.
    发明申请
    NOVEL METHODS 有权

    公开(公告)号：US20220362241A1

    公开(公告)日：2022-11-17

    申请号：US17764070

    申请日：2020-09-25

    Applicant: INTRA-CELLULAR THERAPIES, INC.

    Inventor： Robert E. DAVIS ,  Gretchen SNYDER ,  Peng LI

    IPC: A61K31/4985 ,  C07D471/16 ,  A61P25/08 ,  A61K45/06

    Abstract: The disclosure provides methods for the for treatment of psychosis, such as schizophrenia, or depression (such as bipolar depression) and/or anxiety, comprising administering to a patient in need thereof, (i) a 5-HT2A or 5-HT2A/D2 receptor ligand, for example a substituted heterocycle fused gamma-carboline as described herein, in free, pharmaceutically acceptable salt or prodrug form, and (ii) a nitric oxide donor, separately (sequentially or simultaneously), or in combination (e.g., in a fixed dose combination).

    USES
    8.
    发明申请
    USES 有权

    公开(公告)号：US20250090536A1

    公开(公告)日：2025-03-20

    申请号：US18967095

    申请日：2024-12-03

    Applicant: INTRA-CELLULAR THERAPIES, INC.

    Inventor： Robert E. DAVIS ,  Kimberly E. VANOVER

    IPC: A61K31/519 ,  A61P25/16

    Abstract: The disclosure provides methods, treatments and materials for treating diseases or disorders associated with the dopamine D1 receptor intracellular pathway. In particular, the present disclosure provides for methods of treating such diseases and disorders in combination with a dopamine replacement therapy.

    NOVEL METHODS
    9.
    发明申请
    NOVEL METHODS 有权

    公开(公告)号：US20240415832A1

    公开(公告)日：2024-12-19

    申请号：US18703145

    申请日：2022-10-14

    Applicant: INTRA-CELLULAR THERAPIES, INC.

    Inventor： Peng LI ,  Allen A. FIENBERG ,  Gretchen SNYDER ,  Robert E. DAVIS

    IPC: A61K31/4985 ,  A61P25/36

    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, for use in methods for the treatment for the treatment and/or prevention of fentanyl-analog induced overdose and related sequelae.

Patent Agency Ranking